No Cover Image

Journal article 807 views

Folate Augmentation of Treatment – Evaluation for Depression (FolATED): randomised trial and economic evaluation

Emma Bedson, Diana Bell, Daniel Carr, Ben Carter, Dyfrig Hughes, Andrea Jorgensen, Helen Lewis, Keith Lloyd Orcid Logo, Andrew McCaddon, Stuart Moat, Joshua Pink, Munir Pirmohamed, Seren Roberts, Ian Russell, Yvonne Sylvestre, Richard Tranter, Rhiannon Whitaker, Clare Wilkinson, Nefyn Williams

Health Technology Assessment, Volume: 18, Issue: 48, Pages: 1 - 160

Swansea University Author: Keith Lloyd Orcid Logo

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.3310/hta18480

Abstract

AbstractBackgroundFolate deficiency is associated with depression. Despite the biological plausibility of a causal link, the evidence that adding folate enhances antidepressant treatment is weak.Objectives(1) Estimate the clinical effectiveness and cost-effectiveness of folic acid as adjunct to anti...

Full description

Published in: Health Technology Assessment
ISSN: 1366-5278 2046-4924
Published: 2014
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa39943
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: AbstractBackgroundFolate deficiency is associated with depression. Despite the biological plausibility of a causal link, the evidence that adding folate enhances antidepressant treatment is weak.Objectives(1) Estimate the clinical effectiveness and cost-effectiveness of folic acid as adjunct to antidepressant medication (ADM). (2) Explore whether baseline folate and homocysteine predict response to treatment. (3) Investigate whether response to treatment depends on genetic polymorphisms related to folate metabolism.DesignFolATED (Folate Augmentation of Treatment – Evaluation for Depression) was a double-blind and placebo-controlled, but otherwise pragmatic, randomised trial including cost–utility analysis. To yield 80% power of detecting standardised difference on the Beck Depression Inventory version 2 (BDI-II) of 0.3 between groups (a ‘small’ effect), FolATED trialists sought to analyse 358 participants. To allow for an estimated loss of 21% of participants over three time points, we planned to randomise 453.SettingsClinical – Three centres in Wales – North East Wales, North West Wales and Swansea. Trial management – North Wales Organisation for Randomised Trials in Health in Bangor University. Biochemical analysis – University Hospital of Wales, Cardiff. Genetic analysis – University of Liverpool.ParticipantsFour hundred and seventy-five adult patients presenting to primary or secondary care with confirmed moderate to severe depression for which they were taking or about to start ADM, and able to consent and complete assessments, but not (1) folate deficient, vitamin B12 deficient, or taking folic acid or anticonvulsants; (2) misusing drugs or alcohol, or suffering from psychosis, bipolar disorder, malignancy or other unstable or terminal illness; (3) (planning to become) pregnant; or (4) participating in other clinical research.InterventionsOnce a day for 12 weeks experimental participants added 5 mg of folic acid to their ADM, and control participants added an indistinguishable placebo. All participants followed pragmatic management plans initiated by a trial psychiatrist and maintained by their general medical practitioners.Main outcome measuresAssessed at baseline, and 4, 12 and 25 weeks thereafter, and analysed by ‘area under curve’ (main); by analysis of covariance at each time point (secondary); and by multi-level repeated measures (sensitivity analysis): Mental health – BDI-II (primary), Clinical Global Impression (CGI), Montgomery–Åsberg Depression Rating Scale (MADRS), UKU side effects scale, and Mini International Neuropsychiatric Interview (MINI) suicidality subscale; General health – UK 12-item Short Form Health Survey (SF-12), European Quality of Life scale – 5 Dimensions (EQ-5D); Biochemistry – serum folate, B12, homocysteine; Adherence – Morisky Questionnaire; Economics – resource use.ResultsFolic acid did not significantly improve any of these measures. For example it gained a mean of just 2.9 quality-adjusted life-days [95% confidence interval (CI) from –12.7 to 7.0 days] and saved a mean of just £48 (95% CI from –£292 to £389). In contrast it significantly reduced mental health scores on the SF-12 by 3.0% (95% CI from –5.2% to –0.8%).ConclusionsThe FolATED trial generated no evidence that folic acid was clinically effective or cost-effective in augmenting ADM. This negative finding is consistent with improving understanding of the one-carbon folate pathway suggesting that methylfolate is a better candidate for augmenting ADM. Hence the findings of FolATED undermine treatment guidelines that advocate folic acid for treating depression, and suggest future trials of methylfolate to augment ADM.Trial registrationCurrent Controlled Trials ISRCTN37558856.FundingThis project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 18, No. 48. See the HTA programme website for further project information.
Keywords: Clinical trial, depression folic acid
College: Faculty of Medicine, Health and Life Sciences
Issue: 48
Start Page: 1
End Page: 160

Similar Items